Vanguard Capital Management’s Scribe Therapeutics SCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.5M Buy
+407,630
New +$10.7M ﹤0.01% 2928

Other funds holding SCTX

Vanguard Capital Management's SCTX Position: Q3 2026 in Review

Vanguard Capital Management opened a new position in Scribe Therapeutics (SCTX) in Q3 2026: 407,630 shares worth $7.5M. The stake represents ﹤0.01% of the portfolio and ranks #2928 among its holdings.

63 funds tracked by Wall St. Rank hold SCTX as of Q3 2026.

  • Vanguard Capital Management held 407,630 shares of Scribe Therapeutics worth $7.5M as of Q3 2026.
  • Scribe Therapeutics was a new Vanguard Capital Management position in Q3 2026.
  • Scribe Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2928 holding.
  • 63 funds tracked by Wall St. Rank held Scribe Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.